Tailoring services in opioid treatment programs for patients involved in America’s criminal justice system: national associations and variation by state and Medicaid expansion status

George Pro*, Brooke E. E. Montgomery and Nickolas Zaller

Abstract

Background: Opioid treatment programs (OTPs) are the primary source of medication-assisted treatment (MAT) for many individuals with opioid use disorder, including poor and uninsured patients and those involved in the criminal justice (CJ) system. Substance use treatment services that are tailored to the unique needs of patients often produce better outcomes, but little national research has addressed characteristics associated with whether OTPs offer services specifically tailored to community members involved in the CJ system. Medicaid expansion under the Affordable Care Act has broadly strengthened MAT services, but the role of expansion in supporting MAT services that are specifically tailored towards CJ-involved populations remains unknown. Moreover, it is unknown whether the availability of tailored services varies between Medicaid expansion states.

Methods: We used the 2019 National Survey of Substance Abuse Treatment Services to identify OTPs in the US (n = 1679) and whether they offered services specifically tailored for CJ-involved patients. We used logistic regression to model the association between OTPs offering tailored services and state Medicaid expansion status, adjusted for state-level opioid overdose and community supervision rates.

Results: Nationally, only a quarter of OTPs offered services tailored to CJ populations, and the majority of OTPs (73%) were located in Medicaid expansion states. Compared to OTPs in non-expansion states, OTPs in expansion states demonstrated nearly double the odds of offering tailored services (adjusted odds ratio = 1.90, 95% confidence interval = 1.41–2.57, p < 0.0001). The predicted probability of offering tailored services varied by state; probability estimates for all expansion states were above the national mean, and estimates for all non-expansion states were below the national mean.
Introduction

Opioid use disorders (OUD) and preventable overdose-related deaths continue to drive an ongoing national epidemic. Rates of opioid misuse have risen consistently through 2019, with the majority of overdose-related deaths attributed to fentanyl, including fentanyl mixed with heroin, other opioids, and stimulants [1]. An additional and notable uptick in misuse and overdose has also been identified during the COVID-19 pandemic [2]. Medication-assisted treatment (MAT) for OUDs is effective at reducing opioid misuse and overdose [3], but treatment uptake remains low [4]. Opioid treatment programs (OTPs) are federally licensed facilities that dispense agonist MAT medications (i.e., methadone and buprenorphine). Between 2003 and 2016, the number of OTPs in the US increased by nearly 40% [5]. Private office-based treatment is also increasingly available [6], but OTPs have historically been the primary treatment resource for OUD treatment in most of the US [7]. Despite the number of private office-based buprenorphine prescriptions recently surpassing prescriptions dispensed by OTPs [5], office-based buprenorphine is more likely to be prescribed to White clients, as well as those paying with cash or private insurance [8]. As a result, OTPs remain the primary source of MAT for disadvantaged populations, including people of color and individuals involved in the criminal justice (CJ) system.

There are disproportionate burdens of OUD, treatment barriers, and poor treatment outcomes among individuals in the community who are involved in the CJ system. The majority of CJ-involved individuals are not incarcerated; more than four million Americans are on probation, parole, or are otherwise experiencing some form of correctional supervision by a court [9]. Rates of OUD are substantially higher among CJ-involved individuals compared to their non-involved counterparts, and rates of relapse, overdose, and death are extremely high following release from prison [10]. Lower MAT uptake is related to the inability to pay for services and having limited or no health insurance [11], which are common barriers among CJ-involved populations [12–14]. In addition, Krawczyk and colleagues [15] found that individuals with OUD who were referred to community-based treatment by the CJ system (i.e., courts, probation/parole, diversion) were less likely than their non-CJ-referred counterparts to receive MAT. To highlight the scope of the public health crisis, a 2017 report by the Substance Abuse and Mental Health Services Administration (SAMHSA) [16] showed that 34% of all treatment admissions to publicly funded treatment facilities – or 682,000 people in 1 year – were there for heroin or other opioids. Of those, 94,000 (14%) were referred to treatment by the CJ system. The elevated risk of not receiving MAT showcases the additional challenges in maintaining recovery from OUD among those navigating both the CJ and treatment systems. Critically, CJ-involved community members who need but do not receive MAT are more likely to be re-arrested, have probation revoked, and be re-incarcerated [17].

Given the persistent barriers to initiating and maintaining MAT, there is a need for OTPs to better tailor services to meet the needs of CJ-involved clients. OTPs offer a reliable resource for those who would otherwise not attend private office-based treatment, but additional resources and funding for OTPs could improve maintenance on MAT and other health outcomes. Several strategies could be incorporated into OTPs to tailor services for CJ clients, including connection to MAT immediately upon release [18] and expanding telemedicine services for more rural CJ clients [19]. Reichert and Gleicher [20] found that probation department leaders and staff in Illinois had difficulty in offering guidance about MAT to probationers, largely due to a lack of understanding about the use of MAT, how it is administered, and a generally low level of familiarity with OUD and behavioral health. These findings highlight a unique opportunity for OTPs to tailor MAT services by communicating directly with probation officers about what to expect from a probationer who is receiving MAT. This linkage between MAT providers and CJ agencies is one of several critical steps in the continuum of care for individuals under community supervision [21]. Broadly, services tailored towards CJ clients should serve to improve retention and health and decrease the risks of further involvement with the CJ system and recidivism.

State Medicaid expansions under the Affordable Care Act have broadly increased access to substance use treatment services among poor and marginalized populations, including CJ-involved populations who have historically been un- and under-insured [14, 22, 23]. Increased enrollment in insurance plans in general – and Medicaid specifically – is associated with a notable uptick in health services use among CJ-involved individuals [14], and this increase in the ability to pay for services

Conclusion: Our findings reiterate the role of Medicaid in promoting the adoption of comprehensive OTP services for CJ-involved populations. However, the proportion of OTPs that offered tailored services was relatively low, pointing to the need to continually strengthen Medicaid services and coverage.

Keywords: Opioid use disorder, Opioid treatment programs, Criminal justice, Epidemiology
may be one motivating factor for OTPs to broaden the types of tailored services offered. In this sense, Medicaid expansion may not only improve MAT access but may also serve to strengthen existing OTP services to reach a larger and more diverse clientele. MAT prescriptions increased markedly in states that expanded Medicaid, while making only modest or no gains in states that opted out of expansions [24–27]. Most expansion states saw significant increases in MAT prescriptions without a corresponding increase in prescriptions for opioid pain relievers [28], simultaneously strengthening treatment services and decreasing the supply of opioids that could be diverted to illicit sales. Medicaid expansion has strengthened health services access for CJ-involved individuals, but results from one study by Fry and colleagues [29] that looked at the effect of expansions on CJ-specific outcomes like recidivism were mixed. However, Wen and colleagues [30] attributed reductions in the rates of robbery, aggravated assault, and larceny theft in expansion states to increases in substance use treatment. Medicaid expansion also decrease overall state spending because it is partially offset by savings made in the CJ system [31, 32].

While Medicaid expansions have generally benefited the most vulnerable populations, to our knowledge no research has looked at differences in OTP CJ-tailored services between Medicaid expansion and non-expansion states. We hypothesized that OTPs in expansion states would be more likely than OTPs in non-expansion states to offer tailored services to CJ populations. In addition, we investigated differences between individual states within each of the two expansion groups.

Materials and methods
Data source and variables
We used the National Survey of Substance Abuse Treatment Services (N-SSATS; 2019) [33] to identify OTPs in the US (n = 1679). In short, N-SSATS is planned, directed, and maintained jointly by the Center for Behavioral Health Statistics and Quality, SAMHSA, and the U.S. Department of Health and Human Services. The dataset provides annual facility-level administrative data on the state, organization, structure, and a range of clinical and ancillary services provided by both public and private substance use treatment facilities, including OTPs. No client-level information is collected or included in the dataset. In 2019, the survey response rate of facilities that provided treatment for substance use disorders was 91%. Representatives from each facility responded to a 37-item questionnaire, via secure web-based survey, a paper questionnaire by mail, or a telephone interview. Further details about the survey design, data collection, and the dataset are available through SAMHSA [33].

Our outcome of interest was whether OTPs offer a substance use treatment program or group specifically tailored for CJ-involved clients (yes/no). Importantly, OTPs in N-SSATS are not based in carceral settings, but rather serve the general population, which includes those who may be on probation, parole, or under the supervision of some other community-based court system. This variable was derived from an item in the questionnaire that asked, “For which client categories does this facility at this location offer a substance use treatment program or group specifically tailored for clients in that category? If this facility treats clients in any of these categories but does not have a specifically tailored program or group for them, do not mark the box for that category.” Our outcome was defined by OTPs that marked the only response option that addressed CJ, which was, “Criminal justice clients (other than DUI/DWI)”. Examples of other groups that could be selected include adolescents, seniors or older adults, active duty military, and clients who have experienced trauma. There is no additional information available in N-SSATS that describes each tailored service in more detail.

We defined whether an OTP was in a Medicaid expansion state using a report by the Henry J. Kaiser Family Foundation [34]. To match with the most recent N-SSATS data available (2019), we defined Medicaid expansion as any state that had adopted expansions by the end of 2019, by which time sixteen states had not expanded Medicaid under the Affordable Care Act (AL, FL, GA, ID, KS, MO, MS, NC, NE, OK, SC SD, TN TX, UT, and WI).

Based on a priori understanding of CJ, health, and Medicaid systems, both state-level overdose and community supervision rates were included in our analyses because they are related to both our dependent and independent variables. Specifically, we included state-level, age-adjusted opioid overdose death rates (per 100,000 state residents) as a confounder in our predictive model. Overdose death rates were published by the Henry J. Kaiser Family Foundation and based on publicly available data maintained by the Center for Disease Control and Prevention’s WONDER database of deaths in the US [35]. We also included the state-level community supervision rate (per 100,000 state residents) as a confounder, which was sourced form a report by the Bureau of Justice Statistics [36].

Analysis
We used SAS Software (v9.4) [37] for all analyses. We used logistic regression to model the association between OTPs offering services tailored specifically to CJ-involved clients (outcome) and state Medicaid expansion
status (predictor), adjusted for state-level opioid overdose and incarceration rates. Predicted probabilities for OTPs were calculated at the state level using the PREDICTED function within the LOGISTIC procedure in SAS. We plotted the predicted probability estimates by state and color-coded expansion decisions to visualize probability differences between groups.

Results
A minority of OTPs offered programs or groups specifically tailored towards CJ-involved clients (26%, n = 443), and the majority of OTPs were located in Medicaid expansion states (73%, n = 1238). The mean opioid overdose rate was 17.3 per 100,000 (standard deviation [SD] = 8.99), with the lowest and highest overdose rates identified in Nebraska (3.3 per 100,000) and West Virginia (42.4 per 100,000), respectively. The mean community supervision rate was 1767.4 per 100,000 (SD = 986.0), with the lowest and highest community supervision rates identified in New Hampshire (570.0 per 100,000) and Georgia (5369.0 per 100,000), respectively.

Holding state opioid overdose and community supervision rates constant, the odds of offering CJ-specific programs were significantly higher within OTPs in expansion states, compared to OTPs in non-expansion states (adjusted odds ratio = 1.90, 95% confidence interval = 1.41–2.57, p < 0.0001). We identified no statistically significant association between our confounders (state-level overdose and community supervision rates) and our outcome. The national predicted probability of OTPs offering tailored services to CJ-involved clients was 0.26; notably, point estimates for every expansion state were above the national estimate and point estimates for every non-expansion state were below the national estimate (Fig. 1).

Discussion
Our study demonstrates that Medicaid expansion is clearly and positively associated with OTPs offering services and programs that are specifically tailored to CJ-involved MAT clients. The probability of offering tailored services to CJ populations was higher than the national average in all OTPs in expansion states, and lower than the national average in all OTPs in non-expansion states. This finding is in line with previous work reporting that CJ populations have benefited widely from expanded Medicaid services [38–41]. Generally, treatment and health outcomes are better in services that are uniquely tailored to the needs of a particular group [42–45]. In the context of programs for CJ-involved MAT clients, tailored services could include assistance with health and legal system navigation, overdose prevention in the weeks immediately following release, and assistance integrating back into family and community life while adhering to MAT regimens.

Medicaid expansion is an important factor in identifying state characteristics associated with OTP services. However, Khatri and colleagues [46] recently identified

![Fig. 1 Predicted probability of OTPs offering programs specifically tailored for criminal justice-involved MAT clients](image)
that the use of MAT was already higher in expansion states prior to the implementation of the ACA as far back as 2008. Thus, other factors within expansion states may also help explain their better outcomes. At the same time, the role of Medicaid expansion in bolstering MAT availability for CJ-involved clients cannot be discounted. In the same report, the authors identified a 165% increase in the use of MAT among clients referred to treatment by a CJ agency, while no change in CJ-referred MAT was identified among non-expansion states. Our findings are aligned with those of Khatri and colleagues in that Medicaid expansion is an important driver of MAT access for CJ-involved OUD clients.

OTPs in expansion states may have access to more funding and resources that facilitate the implementation of additional tailored services. Our results also complement previous findings that OTPs in Medicaid expansion states are more likely than OTPs in non-expansion states to offer integrated and comprehensive mental health services [47]. Our analysis suggests that disadvantaged groups in need of MAT, especially those groups impacted by CJ-involvement, may have more opportunities to access a broader range of services in expansion states. Promoting the adoption of Medicaid expansion in states that have not implemented it, as well as strengthening existing programs in expansion states, are potential ways to improve health outcomes among CJ-involved individuals who often have multiple intersecting health exposures [48–51]. Research from San Francisco’s Transitions Clinic Network has demonstrated that tailoring substance use treatment services to the unique needs of CJ-involved individuals is effective in improving health outcomes and reducing recidivism [52]. Similarly, tailored services within OTPs may improve treatment engagement, treatment longevity, and MAT completion, all of which are related to positive outcomes like reduced opioid use and fewer overdoses [3, 53].

Some researchers have recently conceptualized what CJ-tailored services may look like on a broader scale. For example, Brinkley-Rubinstein and colleagues [21] recently proposed the Criminal Justice Continuum of Care for Opioid Users at Risk of Overdose. Their continuum of care could be adapted for use specifically in OTPs, with emphasis on collaborating across the health, law enforcement, and community sectors and the provision of naloxone for overdose prevention. Wrap-around services to assist with employment and housing have long been goals of supporting individuals with drug use disorders and those involved in the CJ system, but the majority of OTPs do not offer supportive services like childcare, transportation, or housing assistance [54]. A public health strategy for dealing with the opioid epidemic includes increasing resource allocation for supportive services [55]. OTPs are positioned well to advance this public health approach by tailoring services to improve MAT outcomes for clients involved in the criminal justice system. Broader state and national health policies likely affect the ability of OTPs to create and sustain such tailored services.

Limitations

While this is the first study to identify national trends in tailored CJ services within OTPs, our definition of programs and services specifically tailored to CJ-involved MAT clients is limited. N-SSATS does not provide detailed information about specific characteristics of tailored programs, nor does it provide demographic characteristics of individual treatment clients. A fuller and more in-depth understanding of tailoring services to vulnerable groups is needed in order to better inform health policy and to optimize clinical MAT practices. Future research could fill this gap by identifying specific characteristics of programs tailored for CJ-involved clients that are the most effective in engaging these clients and improving their outcomes.

Our study only utilized 1 year of N-SSATS data. As a cross-sectional analysis of 2019 data, we are limited to demonstrating associations and are unable to identify a causal pathway between Medicaid expansion and changes in OTP services. Future research may address temporal changes in OTP services and differences by Medicaid expansion status, especially as several states have yet to opt into Medicaid expansion and the opioid and mass incarceration crises are not abating.

Conclusion

Individuals involved in the CJ system make up a sizable portion of the overall MAT clientele in OTPs. OTPs in Medicaid expansion states are significantly more likely than OTPs in non-expansion states to offer programs specifically tailored to the needs of CJ-involved clients, reiterating the role of Medicaid in promoting the adoption of comprehensive services that provide more support to CJ-involved populations. However, tailored services remained low across all 50 states, with no state having more than 40% of its OTPs offering such programs. While promoting the adoption of Medicaid expansion is critical, this research also point to the need to continually strengthen MAT services in all states, including expansion states, with a focus on developing new services and programs that specifically target populations with the highest need.

Abbreviations

OTP: Opioid treatment program; OUD: Opioid use disorder; MAT: Medication-assisted treatment; CJ: Criminal justice; N-SSATS: National Survey of Substance Abuse Treatment Services; SAMHSA: Substance Abuse and Mental Health Services Administration
Acknowledgements
Not applicable.

Authors’ contributions
GP made substantial contributions to the conception and design of the work; acquired, analyzed, and interpreted the data; drafted the first manuscript draft; approved of the submitted version; and, agreed to be personally accountable for the author’s own contributions and to ensure that questions related to the accuracy or integrity of any part of the work will be appropriately investigated, resolved, and the resolution will be appropriately documented in the literature.

BEEM made substantial contributions to the conception and design of the work; interpreted the data; substantially revised the manuscript; approved of the submitted version; and, agreed to be personally accountable for the author’s own contributions and to ensure that questions related to the accuracy or integrity of any part of the work will be appropriately investigated, resolved, and the resolution will be appropriately documented in the literature.

NZ made substantial contributions to the conception and design of the work; interpreted the data; substantially revised the manuscript; approved of the submitted version; and, agreed to be personally accountable for the author’s own contributions and to ensure that questions related to the accuracy or integrity of any part of the work will be appropriately investigated, resolved, and the resolution will be appropriately documented in the literature.

Declarations

Ethics approval and consent to participate
No human subjects were involved in this research. As an epidemiologic study addressing state health systems, no human subjects approval or determination was sought. Specifically, this study is based on administrative, facility-level data about characteristics of opioid treatment programs. No individual-level data was used in this study. The facility-level dataset (The National Survey of Substance Abuse Treatment Services) is free and publicly available for download online through SAMHSA.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Accepted: 8 June 2021
Published online: 19 June 2021

References
1. O’Donnell J, Gladden R, Mattson C, Hunter C, Davis N. Vital signs: characteristics of drug overdose deaths involving opioids and stimulants - 24 states and the District of Columbia, January - June 2019. Morbidity Mortal Weekly Rep (MMWR). 2020;69(35):1189–97. https://doi.org/10.15585/mmwr.mm6935a1.

2. American Medical Association. Issue Brief: Reports of increases in opioid- and other drug-related overdose and other concerns during COVID pandemic. American Medical Association Advocacy Resource Center. Updated December 9, 2020. 2020
3. Bell J, Strang J. Medication treatment of opioid use disorder. Biol Psychiatry. 2020;87(11):82–8. https://doi.org/10.1016/j.biopsych.2019.06.020.
4. Jones C, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105(8):e55–63. https://doi.org/10.2105/A JPH.2015.302664.
5. Alderks C. Trends in the use of methadone, buprenorphine, and extended-release naltrexone at substance abuse treatment facilities: 2003–2015 (update). Rockville, Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2017.
6. Rhee T, Rosenheck R. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States. Addiction. 2019;114(11):1992–9. https://doi.org/10.1111/add.14733.
7. U.S. Department of Health and Human Services, Office Based Opioid Treatment (OBOT). Indian Health Service. Treatment Program Overview. 2020.
8. Lagisetty P, Ross R, Bohnet A, Clay M, Maust D. Buprenorphine treatment divide by race/ethnicity and payment. JAMA Psychiatry. 2019;76(9):979–81. https://doi.org/10.1001/jamapsychiatry.2019.0876.
9. Jones A. Correctional control 2018: incarceration and supervision by state. Prison Policy Initiative. Press Release. 2018.
10. Binswanger I, Blatchford P, Mueller S, Stern M. Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999-2009. Ann Intern Med. 2013;159(9):592–600. https://doi.org/10.7326/M0003-4819-159-9-201311050-00005.
11. Cantone R, Garvey B, O’Neill A, Fleishman J, Cohen D, Muench J, et al. Predictors of medication-assisted treatment initiation for opioid use disorder in an interdisciplinary primary care model. J Am Board Fam Med. 2019;32(5):724–31.
12. Jannetta J, Dorn S, Kurs E, Reginal T, Marks J, Serfaty K, et al. Strategies for connecting justice-involved populations to health coverage and care: The Urban Institute. Health Policy Center and Justice Policy Center. Policy Guide; 2018.
13. Rich J, Chandler R, Williams B, Dumont D, Wang E, Taxman F, et al. How health care reform can transform the health of criminal justice-involved individuals. Health Aff. 2014;33(3).
14. Farrell C, Gottlieb A. The effect of health insurance on health care utilization in the justice-involved population: United States, 2014-2016. Am J Public Health. 2020;110(S1):S78–84. https://doi.org/10.2105/A JPH.2019.305399.
15. Krawczyk N, Picher C, Feder K, Saloner B. Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine. Health Aff. 2017;36(12).
16. Substance Abuse and Mental Health Services Administration. Treatment Episode Dataset (TEDS): 2017. Admissions to and discharges from publicly-funded substance use treatment center for Behavioral Health Statistics and Quality 2019.
17. Substance Abuse and Mental Health Services Administration. Medication-assisted treatment (MAT) in the criminal justice system: brief guidance to the states. US Department of Health and Human Services 2019.
18. Clemens-Cope L, Kotonias C, Marks J. Providing medications at release: Connecticut and Rhode Island. The Urban Institute Health Policy Center and Justice Policy Center Washington, DC. 2017.
19. Weinstein BA, Greenblatt A, Chang J, Himelhoch S, Welsh C. Expanding access to buprenorphine treatment in rural areas with the use of telemedicine. Am J Addict. 2018;27(8):612–21. https://doi.org/10.1111/ajad.12050.
20. Rechert J, Gleicher L. Probation clients’ barriers to access and use of opioid use disorder medications. Health Justice. 2019;7(10):1–11.
21. Brinkley-Rubinstein L, Zaller N, Martino S, Cloud D, McClauelty E, Heise A, et al. Criminal justice continuu for opioid users at risk of overdose. Addict Behav. 2018;86:104–10. https://doi.org/10.1016/j.addbeh.2018.02.024.
22. Winkelman T, Kieffer E, Goold S, Morenoff J, Cross K, Ayanian J. Health insurance trends and access to behavioral healthcare among justice-involved individuals - United States, 2008-2014. J Gen Intern Med. 2016; 31(12):1523–9. https://doi.org/10.1007/s11606-016-3845-5.
23. Wachino V, Choi H, Davis M. The affordable care act, insurance coverage, and health care utilization of previously incarcerated young men: 2008-2015. Am J Public Health. 2017;107(5):807–11. https://doi.org/10.2105/AJPH.2017.303703.

24. Sharp A, Jones A, Sherwood J, Kutsa O, Honermann B, Millett G. Impact of Medicaid expansion on access to opioid analgesic medications and medication-assisted treatment. Am J Public Health. 2018;108(5):642–8. https://doi.org/10.2105/AJPH.2018.304338.

25. Wen H, Hockenberry J, Borders T, Druss B. Impact of Medicaid expansion on Medicaid-covered utilization of buprenorphine for opioid use disorder treatment. Med Care. 2017;55(4):336–41. https://doi.org/10.1016/j.mca.2017.02.004.

26. Pro G, Utter J, Habershon S, Baldwin J. Dual mental health diagnoses predict the receipt of medication-assisted opioid treatment: associations moderated by state Medicaid expansion status, race/ethnicity and gender, and year. Drug Alcohol Depend. 2020;209:107952.

27. Mojtabar R, Mauro C, Wall M, Barry C, Olsson M. The affordable care act and opioid agonist therapy for opioid use disorder. Psychiatr Serv. 2019;70(7):617–20. https://doi.org/10.1176/appps.201900025.

28. Saloner B, Levin J, Chang H, Jones C, Alexander G. Changes in buprenorphine-naloxone and opioid pain reliever prescriptions after the affordable care act Medicaid expansion. JAMA Netw Open. 2018;1(4):e181588. https://doi.org/10.1001/jamanetworkopen.2018.1588.

29. Fry C, McGuire T, Frank R. Medicaid expansion’s spillover to the criminal justice system: evidence from six urban counties. Russell Sage Foundation J Soc Sci. 2020;6(2).

30. Wen H, Hockenberry J, Cummings J. The effect of Medicaid expansion on crime reduction: evidence from HFA waiver expansions. J Public Econ. 2017;154:67–94. https://doi.org/10.1016/j.jpubeco.2017.09.001.

31. Rudowitz R, Antonisse L. Implications of the ACA Medicaid expansion: a look at the data and evidence. Henry J Kaiser Family Foundation. May 2018 Issue Brief 2018.

32. Bachrach D, Boozang P, Herring A, Reyneri D. States expanding Medicaid can help address the opioid epidemic. The Henry J Kaiser Family Foundation Issue Brief June 17, 2019.

33. Substance Abuse and Mental Health Services Administration. National survey of substance abuse treatment services (NS-SATs): 2019 data on substance abuse treatment facilities. Rockville: Department of Health and Human Services; 2020.

34. Henry, J Kaiser Family Foundation. Status of state Medicaid expansion decisions: interactive map. Medicaid Nov 02, 2020.

35. Henry J Kaiser Family Foundation. Opioid overdose death rates and all drug overdose death rates per 100,000 population (age-adjusted). Henry J Kaiser Family Foundation. State Health Facts: Opioid Overdose Deaths. 2020.

36. Kaeble D, Alper M. Probation and Parole in the United States, 2017-2018. US Department of Justice Office of Justice Programs Bureau of Justice Statistics. August 2020, NCJ 252072. 2020.

37. SAS software. Copyright 2021, SAS Institute Inc. SAS and all other SAS trademarks of SAS Institute Inc., Cary, NC, USA.

38. SAS Institute Inc. SAS Institute Inc product or service names are registered trademarks or trademarks of SAS Institute Inc., Cary, NC, USA.

39. Zaller N, Cloud D, Brinkley Rubinstein L, Martino S, Bovair B, Brockmann B. The importance of Medicaid expansion for criminal justice in the south. Health Justice. 2017;5(2).

40. Howard J, Solan M, Neptune J, Mcllgen L, Budernt J, Avery K. The importance of Medicaid coverage for criminal justice involved individuals reentering into their communities. ASPE Issue Brief. Department of Health and Human Services. 2016.

41. Bandara S, Huskamp H, Riedel L, McGinty E, Webster D, Toone R, et al. Leveraging the affordable care act to enroll justice-involved populations in Medicaid: state and local efforts. Health Aff. 2015;34(12).

42. Alexander J, Nahra T, Harris Lemak C, Pollack H, Campbell C. Tailored treatment in the outpatient substance abuse treatment sector. 1995-2006. J Subst Abus Treat. 2008;34(3):282–92. https://doi.org/10.1016/j.sjat.2007.04.009.

43. Marsh J, Cao D, Guerrero E, Shin H. Need-service matching in substance abuse treatment: racial/ethnic differences. Eval Program Planning. 2009;32(1):43–51. https://doi.org/10.1016/j.evalproplann.2008.09.003.

44. Blank M, Eisenberg M. Tailored treatment for HIV+ persons with mental illness: the intervention cascade. J Acquired Immune Deficiency Synd. 2013;63(1):544–58. https://doi.org/10.1097/QAI.0b013e318293067b.

45. Oser C, Knudsen H, Staton-Tindall M, Leukfeldt C. The adoption of wraparound services among substance abuse treatment organization serving criminal offenders: the role of a women-specific program. Drug Alcohol Depend. 2009;103(Supplement 1):582–90.

46. Khatri U, Howell B, Winkelman T. Medicaid expansion increased medications for opioid use disorder among adults referred by criminal justice agencies. Health Aff. 2021;40(4):562–70. https://doi.org/10.1377/hlthaff.2020.01251.

47. Pro G, Ianoz Z, Campilan R, Habershon S, Campilan C, Wheeler D, et al. The role of state Medicaid expansions in integrating comprehensive mental health services into opioid treatment programs: differences across the rural/urban continuum. Community Ment Health J. 2020;E-publication ahead of print.

48. Spaulding A, Anderson E, Khan M, Taborda-Vidarte C, Phillips J, HIV and HCV in U. S prisons and jails: the correctional facility as a bellwether over time for the community’s infections. AIDS. 2017;19:134–47.

49. Pettman D, Jordan A. The syndemic of opioid misuse, overdose, HCV, and HIV: structural-level causes and interventions. Current HIV/AIDS Rep. 2018;15(2):96–112. https://doi.org/10.1007/s11904-018-0390-3.

50. Vaughn M, Salas-Wright C, Delisi M, Piquero A. Health associations of drug-involved and criminal-justice-involved adults in the United States. Crim Justice Behav. 2013;41(3):318–36.

51. Tolou-Shams M, Harrison A, Hirschtritt M, Dauria E, Barr-Walker J. Substance use and HIV among justice-involved youths: intersecting risks. Current HIV/AIDS Rep. 2019;16(1):37–47. https://doi.org/10.1007/s11904-019-00424-x.

52. Shawit S, Aminawung J, Bimbaum N, Greenberg S, Berthold T, Fishman A, et al. Transitions clinic network: challenges and lessons in primary care for people released from prison. Health Aff. 2017;36(6).

53. Pro G, Utter J, Crann J, Baldwin J. Racial/ethnic and gender differences in associations between medication-assisted therapy and reduced opioid use between outpatient admission and discharge. J Psychoactive Drugs. 2020;52(2):186–94. https://doi.org/10.1080/02791072.2020.1717685.

54. Jones C, Byrd D, Clarke T, Campbell T, Oluoha C, McCance-Katz E. Characteristics and current clinical practices of opioid treatment programs in the United States. Drug Alcohol Depend. 2019;205(1):107616. https://doi.org/10.1016/j.drugalcdep.2019.107616.

55. Saloner B, Mcintyre G, Beletsky L, Bluthenthal R, Beyrer C, Bötticelli M, et al. A public health strategy for the opioid crisis. Public Health Rep. 2018;133(1):S24–34. https://doi.org/10.1177/0033354917793627.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.